ILB

DRUG2 trials

Sponsors

Oslo University Hospital HF, TikoMed AB

Conditions

Amyotrophic Lateral Sclerosis

Phase 2

A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

TerminatedNCT03613571

TikoMed ABAmyotrophic Lateral Sclerosis

Start: 2018-08-15End: 2019-08-20Updated: 2023-06-12

A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis

Not yet recruitingCTIS2024-513927-18-00

Oslo University Hospital HFAmyotrophic Lateral Sclerosis

Target: 116Updated: 2026-01-13